Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
129Xe MRI study of single-inhaler triple therapy in COPD
ISRCTN88783091Phase 4Recruiting
- Sponsor
- Western University
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluticasone, umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by Western University. Primary endpoints: Ventilation defect percent by 129Xe MRI and Forced expiratory volume in 1 second. Started Nov 2025; status: recruiting.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN88783091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88783091.